futuuropen
Bumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
SÍ
—
NO
—
Proveedor: Alzheimer's disease
Liquidity: $246.68
actualizado: Mar 14, 2026, 06:01 AM
Proveedor: Alzheimer's disease
Liquidity: $246.68
actualizado: Mar 14, 2026, 06:01 AM